Pancreatic Cancer Research

ResearcherGlaxoSmithKline (United States)No recent work listed

Philip A. Harris

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5189-3326; OpenAlex author ID A5038108029. Sources: OpenAlex.

Their work

Papers
2
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper

Papers 2

  1. Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer. Co-author DOI 10.1021/acsmedchemlett.9b00108↗
  2. RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2018.10.006↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. George Miller · 2 shared papers, 2018–2019 · strength 0.12
  2. Robert W. Marquis · 1 shared paper, 2019 · strength 0.07
  3. Deirdre Jill Cohen · 1 shared paper, 2018 · strength 0.05
  4. Emma Kurz · 1 shared paper, 2018 · strength 0.05
  5. Berk Aykut · 1 shared paper, 2018 · strength 0.05
  6. Fei Li · 1 shared paper, 2018 · strength 0.05
  7. Wei Wang · 1 shared paper, 2018 · strength 0.05
  8. Atsuo Ochi · 1 shared paper, 2018 · strength 0.05
  9. Joshua Leinwand · 1 shared paper, 2018 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.